Jasper Therapeutics, Inc.
JSPR
$0.46
$0.00-0.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 51.43% | 29.89% | -25.81% | 12.66% | -30.50% |
| Total Depreciation and Amortization | 26.64% | -11.24% | -7.53% | 13.88% | -54.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -296.22% | -20.57% | 6.49% | -4.57% | -1.08% |
| Change in Net Operating Assets | -5,103.21% | -102.11% | 328.58% | -561.28% | -56.17% |
| Cash from Operations | -28.64% | -10.00% | 32.35% | -8.08% | -50.40% |
| Capital Expenditure | -- | 100.00% | -- | -- | 64.96% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | 100.00% | -80.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -100.00% | -75.00% | 105.26% | 72.26% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 360.62% | -- | -- | 3,733.33% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -101.20% | 360.62% | -- | -- | 3,733.33% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -294.99% | 222.61% | 59.33% | -9.46% | -45.74% |